Influence of betahistine repeated administration on a weight gain and selected metabolic parameters in the model of excessive eating in rats.
Animals
Anti-Obesity Agents
/ administration & dosage
Betahistine
/ administration & dosage
Diet
Dietary Fats
Female
Histamine Agonists
/ administration & dosage
Hormones
/ metabolism
Hyperphagia
/ metabolism
Metabolism
/ drug effects
Motor Activity
/ drug effects
Rats
Rats, Wistar
Sugars
Weight Gain
/ drug effects
Betahistine
Excessive eating model
Palatable diet
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
09
04
2021
revised:
24
06
2021
accepted:
28
06
2021
pubmed:
7
7
2021
medline:
16
12
2021
entrez:
6
7
2021
Statut:
ppublish
Résumé
It is important to search for a promising therapeutic target or small molecules that can control excessive eating since limiting the intake of foods, especially tasty ones, could be effective in the treatment or prevention of obesity. Some studies indicate betahistine as an unique drug having the ability to ameliorate, for example, antipsychotic-induced weight gain. This study aimed to determine whether repeated administration of betahistine (histamine H1R agonist and H3R antagonist) could be beneficial in reducing the intake of tasty foods or the body's response to overeating via mechanisms such as by influencing the levels of hormones involved in the regulation of food intake or the levels of selected metabolic parameters. Studies were performed in the excessive eating model in rats, which perfectly illustrates the harmful high-caloric intake from freely available tasty products rich in sugar and fat. Our results indicated that repeated administration of betahistine to rats caused lower gain of body mass compared to the control rats fed palatable feed. Interestingly, betahistine treatment increased the consumption of cheese, which is a source of histamine. Although betahistine did not prevent the development of metabolic disorders, such as reduced glucose tolerance, in test animals, it significantly increased the level of high-density lipoprotein cholesterol, which could certainly be considered beneficial. Further studies should be conducted to investigate the effect of repeated administration of betahistine on satiety, gastrointestinal disorders, and the preference for histamine-containing foods.
Identifiants
pubmed: 34229247
pii: S0753-3322(21)00674-0
doi: 10.1016/j.biopha.2021.111892
pii:
doi:
Substances chimiques
Anti-Obesity Agents
0
Dietary Fats
0
Histamine Agonists
0
Hormones
0
Sugars
0
Betahistine
X32KK4201D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111892Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.